260 related articles for article (PubMed ID: 34407819)
21. Application of Saccharomyces cerevisiae var. boulardii in food processing: a review.
Lazo-Vélez MA; Serna-Saldívar SO; Rosales-Medina MF; Tinoco-Alvear M; Briones-García M
J Appl Microbiol; 2018 Oct; 125(4):943-951. PubMed ID: 29961970
[TBL] [Abstract][Full Text] [Related]
22. Dual Agarolytic Pathways in a Marine Bacterium,
Yu S; Yun EJ; Kim DH; Park SY; Kim KH
Appl Environ Microbiol; 2020 Mar; 86(6):. PubMed ID: 31924614
[No Abstract] [Full Text] [Related]
23. A Tunable and Expandable Transactivation System in Probiotic Yeast
Kwak S; Mahmud B; Dantas G
ACS Synth Biol; 2022 Jan; 11(1):508-514. PubMed ID: 34939781
[TBL] [Abstract][Full Text] [Related]
24. Fungemia following Saccharomyces cerevisiae var. boulardii probiotic treatment in an elderly patient.
Landaburu MF; López Daneri GA; Relloso S; Zarlenga LJ; Vinante MA; Mujica MT
Rev Argent Microbiol; 2020; 52(1):27-30. PubMed ID: 31262611
[TBL] [Abstract][Full Text] [Related]
25. Transcriptome-wide differences between Saccharomyces cerevisiae and Saccharomyces cerevisiae var. boulardii: Clues on host survival and probiotic activity based on promoter sequence variability.
Pais P; Oliveira J; Almeida V; Yilmaz M; Monteiro PT; Teixeira MC
Genomics; 2021 Mar; 113(2):530-539. PubMed ID: 33482324
[TBL] [Abstract][Full Text] [Related]
26. Development of a Novel ATP Bioluminescence Assay Based on Engineered Probiotic
Park JS; Kim YW; Kim H; Kim SK; Park K
J Microbiol Biotechnol; 2023 Nov; 33(11):1506-1512. PubMed ID: 37482802
[TBL] [Abstract][Full Text] [Related]
27. Heterologous Expression of the Leuconostoc Bacteriocin Leucocin C in Probiotic Yeast Saccharomyces boulardii.
Li R; Wan X; Takala TM; Saris PEJ
Probiotics Antimicrob Proteins; 2021 Feb; 13(1):229-237. PubMed ID: 32567021
[TBL] [Abstract][Full Text] [Related]
28. Production of a synbiotic composed of galacto-oligosaccharides and Saccharomyces boulardii using enzymatic-fermentative method.
Rengel Dos Passos F; Lopes Maestre K; Florêncio da Silva B; Rodrigues AC; Contini Triques C; Alves Garcia H; Fagundes-Klen MR; Antonio da Silva E; Fiorese ML
Food Chem; 2021 Aug; 353():129486. PubMed ID: 33735774
[TBL] [Abstract][Full Text] [Related]
29. Improving therapeutic protein secretion in the probiotic yeast Saccharomyces boulardii using a multifactorial engineering approach.
Durmusoglu D; Al'Abri I; Li Z; Islam Williams T; Collins LB; Martínez JL; Crook N
Microb Cell Fact; 2023 Jun; 22(1):109. PubMed ID: 37287064
[TBL] [Abstract][Full Text] [Related]
30. β-Galactomannan and Saccharomyces cerevisiae var. boulardii modulate the immune response against Salmonella enterica serovar Typhimurium in porcine intestinal epithelial and dendritic cells.
Badia R; Brufau MT; Guerrero-Zamora AM; Lizardo R; Dobrescu I; Martin-Venegas R; Ferrer R; Salmon H; Martínez P; Brufau J
Clin Vaccine Immunol; 2012 Mar; 19(3):368-76. PubMed ID: 22301691
[TBL] [Abstract][Full Text] [Related]
31. Incidence of Saccharomyces cerevisiae fungemia in hospitalised patients administered Saccharomyces boulardii probiotic.
Wombwell E; Bransteitter B; Gillen LR
Mycoses; 2021 Dec; 64(12):1521-1526. PubMed ID: 34585799
[TBL] [Abstract][Full Text] [Related]
32. Novel insights in genetic transformation of the probiotic yeast Saccharomyces boulardii.
Douradinha B; Reis VC; Rogers MB; Torres FA; Evans JD; Marques ET
Bioengineered; 2014; 5(1):21-9. PubMed ID: 24013355
[TBL] [Abstract][Full Text] [Related]
33. Effect of microencapsulation on
Ghorbani-Choboghlo H; Nikaein D; Khosravi AR; Rahmani R; Farahnejad Z
Iran J Microbiol; 2019 Apr; 11(2):160-165. PubMed ID: 31341571
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of the impact of polypeptide-p on diabetic rats upon its cloning, expression, and secretion in Saccharomyces boulardii.
Yamchi A; Rahimi M; Javan B; Abdollahi D; Salmanian M; Shahbazi M
Arch Microbiol; 2023 Dec; 206(1):37. PubMed ID: 38142245
[TBL] [Abstract][Full Text] [Related]
35. Molecular tools for differentiating probiotic and clinical strains of Saccharomyces cerevisiae.
Posteraro B; Sanguinetti M; Romano L; Torelli R; Novarese L; Fadda G
Int J Food Microbiol; 2005 Sep; 103(3):295-304. PubMed ID: 16099314
[TBL] [Abstract][Full Text] [Related]
36. Anticancer Properties of Probiotic Saccharomyces boulardii Supernatant on Human Breast Cancer Cells.
Pakbin B; Dibazar SP; Allahyari S; Javadi M; Amani Z; Farasat A; Darzi S
Probiotics Antimicrob Proteins; 2022 Dec; 14(6):1130-1138. PubMed ID: 35094296
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic potential of Saccharomyces boulardii in liver diseases: from passive bystander to protective performer?
Cui B; Lin L; Wang B; Liu W; Sun C
Pharmacol Res; 2022 Jan; 175():106022. PubMed ID: 34883213
[TBL] [Abstract][Full Text] [Related]
38. Saccharomyces cerevisiae fungemia: Risk factors, outcome and links with S. boulardii-containing probiotic administration.
Poncelet A; Ruelle L; Konopnicki D; Miendje Deyi VY; Dauby N
Infect Dis Now; 2021 May; 51(3):293-295. PubMed ID: 33934809
[TBL] [Abstract][Full Text] [Related]
39. Anticancer Properties of Saccharomyces boulardii Metabolite Against Colon Cancer Cells.
Pakbin B; Allahyari S; Dibazar SP; Peymani A; Haghverdi MK; Taherkhani K; Javadi M; Mahmoudi R
Probiotics Antimicrob Proteins; 2024 Feb; 16(1):224-232. PubMed ID: 36547769
[TBL] [Abstract][Full Text] [Related]
40. Saccharomyces boulardii administration changes gut microbiota and reduces hepatic steatosis, low-grade inflammation, and fat mass in obese and type 2 diabetic db/db mice.
Everard A; Matamoros S; Geurts L; Delzenne NM; Cani PD
mBio; 2014 Jun; 5(3):e01011-14. PubMed ID: 24917595
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
